SciSparc Ltd.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.33
- 52-Week Range
- $0.23 – $29.88
- Market Cap
- $665.38K
- P/E (TTM)
- 0.00
- EPS (TTM)
- 248.24
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.04
- PEG Ratio
- —
- Return on Equity
- -164.49%
- Return on Assets
- -26.05%
- Gross Margin
- 950.81%
- Operating Margin
- -725.18%
- Profit Margin
- 0.00%
- Current Ratio
- 0.87
- Debt/Equity
- 0.24
- Total Debt
- $2.68M
- Free Cash Flow
- $-343.25K
- Revenue Growth
- -38.40%
- Earnings Growth
- —
- Enterprise Value
- $5.73M
Market Snapshot
About
SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The company leverages a proprietary CBD-based drug platform to develop treatments for conditions including Tourette syndrome, Alzheimer disease, and autism spectrum disorder.